NASDAQ:CRME - Cardiome Pharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.33
+0.30 (1.20%)
Get New Cardiome Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRME

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cardiome Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.33.

This chart shows the closing price for CRME for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Cardiome Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018HC WainwrightSet Price TargetBuy$10.00Medium
3/21/2018Canaccord GenuitySet Price TargetBuy$5.00Low
3/21/2018HC WainwrightSet Price TargetBuy$10.00High
12/15/2017MackieUpgradeBuyLow
11/22/2017HC WainwrightReiterated RatingBuy$9.50N/A
11/15/2017Canaccord GenuitySet Price TargetBuy ➝ Buy$8.00 ➝ $5.00N/A
8/22/2017HC WainwrightSet Price TargetBuy$10.00High
8/21/2017Canaccord GenuitySet Price TargetBuy$8.00High
8/9/2017HC WainwrightSet Price TargetBuy$10.00High
7/17/2017Canaccord GenuityReiterated RatingBuy$8.00High
3/8/2017HC WainwrightSet Price TargetBuy$10.00Low
12/22/2016SVB LeerinkInitiated CoverageOutperform$4.75N/A
11/9/2016Bloom BurtonReiterated RatingBuyN/A
10/12/2016MackieReiterated RatingSpeculative Buy ➝ Hold$5.10 ➝ $3.50N/A
8/15/2016Brean CapitalReiterated RatingBuy$10.00 ➝ $7.00N/A
(Data available from 8/3/2016 forward)
Cardiome Pharma logo
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $2.33
Low: $2.30
High: $2.45

50 Day Range

MA: N/A

52 Week Range

Now: $2.33
Low: $1.29
High: $4.84

Volume

90,444 shs

Average Volume

135,322 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiome Pharma?

The following Wall Street sell-side analysts have issued stock ratings on Cardiome Pharma in the last year:
View the latest analyst ratings for CRME.

What is the current price target for Cardiome Pharma?

0 Wall Street analysts have set twelve-month price targets for Cardiome Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cardiome Pharma in the next year.
View the latest price targets for CRME.

What is the current consensus analyst rating for Cardiome Pharma?

Cardiome Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CRME.

What other companies compete with Cardiome Pharma?

How do I contact Cardiome Pharma's investor relations team?

Cardiome Pharma's physical mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company's listed phone number is 604-677-6905 and its investor relations email address is [email protected] The official website for Cardiome Pharma is www.cardiome.com.